Back to Report Store Home

Seasonal Influenza Vaccine Market in Asia-Pacific Region - Threat of Pandemic Influenza and Increasing Vaccination Coverage to Drive Growth

  • Published: Dec-2010
  • Report Code: GBIHC055MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Introduction

2.1 Influenza

2.2 GBI Research Report Guidance

3 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Market Overview

3.1 Production Cycle for the Seasonal Influenza Vaccines

3.2 The Asia-Pacific Region Seasonal Influenza Vaccine Market

3.3 Revenue Forecasts for the Seasonal Influenza Vaccine Market

3.4 Geographical Segmentation

4 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Geographical Landscape

4.1 Revenue Analysis by Geography

4.2 Australia

4.2.1 Vaccination Pattern

4.2.2 Cost of Vaccine

4.2.3 Total Revenue

4.3 New Zealand

4.3.1 Vaccination Pattern

4.3.2 Cost of Vaccine

4.3.3 Total Revenue

4.3.4 Major Players by Market Share

4.4 Taiwan

4.4.1 Vaccination Pattern

4.4.2 Cost of Vaccine

4.4.3 Total Revenue

4.4.4 Major Players by Market Share

4.5 Philippines

4.5.1 Vaccination Pattern

4.5.2 Cost of Vaccine

4.5.3 Total Revenue

4.5.4 Major Players by Market Share

4.6 Malaysia

4.6.1 Vaccination Pattern

4.6.2 Cost of Vaccine

4.6.3 Total Revenue

4.6.4 Major Players by Market Share

4.7 Hong Kong

4.7.1 Vaccination Pattern

4.7.2 Cost of Vaccine

4.7.3 Total Revenue

4.7.4 Major Players by Market Share

4.8 Singapore

4.8.1 Vaccination Pattern

4.8.2 Cost of Vaccine

4.8.3 Total Revenue

4.8.4 Major Players by Market Share

5 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Drivers and Restraints

5.1 Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region

5.1.1 Threat of Pandemic Influenza

5.1.2 Increasing Vaccination Coverage for Seasonal Influenza Vaccines

5.1.3 Emergence of Novel Production Technologies and Vaccines

5.1.4 Population Growth

5.1.5 Economic Reasons

5.2 Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region

5.2.1 Entry Barriers in the Seasonal Influenza Vaccine Market

5.2.2 Variable Demand

5.2.3 Limited Production Capacity

5.3 Australia

5.3.1 Drivers

5.3.2 Restraints

5.4 New Zealand

5.4.1 Drivers

5.4.2 Restraints

5.5 Taiwan

5.5.1 Drivers

5.5.2 Restraints

5.6 Philippines

5.6.1 Drivers

5.6.2 Restraints

5.7 Malaysia

5.7.1 Drivers

5.7.2 Restraints

5.8 Hong Kong

5.8.1 Drivers

5.8.2 Restraints

5.9 Singapore

5.9.1 Drivers

5.9.2 Restraints

6 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Regulatory Landscape

6.1 Registration Process and Regulations in Australia

6.2 Registration Process and Regulations in New Zealand

6.3 Registration Process and Regulations in Taiwan

6.4 Registration Process and Regulations in the Philippines

6.5 Registration Process and Regulations in Malaysia

6.6 Registration Process and Regulations in Hong Kong

6.7 Registration Process and Regulations in Singapore

7 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Pipeline Analysis

7.1 Seasonal Influenza Vaccines – Promising Vaccines under Clinical Development

7.2 Profiles for Promising Vaccines under Clinical Development

7.2.1 Optaflu

7.2.2 GSK2186877A

7.2.3 Intanza / Flu-ID

7.2.4 Fluad Pediatric

7.3 Research and Development Pipeline

8 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Competitive Landscape

8.1 Major Seasonal Influenza Vaccines Marketed in the APAC Region

8.1.1 Fluarix

8.1.2 Vaxigrip

8.1.3 Influvac

8.1.4 Fluvax

8.1.5 Agrippal

8.2 Key Areas Focused for R&D

8.3 Competitive Profiling

8.3.1 Sanofi Pasteur

8.3.2 GlaxoSmithKline Biologicals

8.3.3 Abbott Laboratories (Solvay Pharmaceuticals)

8.3.4 CSL Biotherapies

8.3.5 Novartis Vaccines

8.3.6 Adimmune Corporation

8.3.7 Crucell N.V. (Berna Biotech)

9 Seasonal Influenza Vaccine Market in Asia-Pacific Region: M&A Landscape

9.1 Overview

9.1.1 AstraZeneca Acquires Medimmune

9.1.2 Sanofi Aventis Acquires Acambis

9.1.3 Mymetics Acquires Virosome Biologicals

9.1.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock

9.1.5 Novartis to Acquire a Majority Stake in Zhejiang Tianyuan

9.1.6 Abbott Laboratories Acquires Solvay Pharmaceuticals

9.1.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno

9.1.8 Johnson & Johnson to Acquire a Majority Stake in Crucell

9.2 M&A Deals by Value

9.3 M&A Deals by Geography

9.4 R&D Licensing Agreements for the Period 2007-2010

9.4.1 Crucell Enters Into License Agreement With ADImmune

9.4.2 MedImmune Enters Into Licensing Agreement With Sanofi Pasteur

9.4.3 Vivalis Enters Into Licensing Agreement With GlaxoSmithKline

9.4.4 Vivalis Enters Into Licensing Agreement With Nobilon International

9.4.5 MedImmune Enters Into Licensing Agreement With GlaxoSmithKline

9.4.6 Hemispherx Biopharma Enters Into Licensing Agreement With BIKEN

9.4.7 MedImmune Enters Into Licensing Agreement With BIKEN

9.4.8 MedImmune Enters Into Licensing Agreement With Omninvest

9.4.9 OPKO Health Enters Into Licensing Agreement With Academia Sinica

9.4.10 AltraVax Enters Into Licensing Agreement With Maxygen

9.4.11 NasVax Announces Option Licensing Agreement With Novartis

9.4.12 iBio Enters Into Licensing Agreement With G-Con

9.4.13 Deals by Geography

10 Seasonal Influenza Vaccine Market in Asia-Pacific Region: Appendix

10.1 Market Definitions

10.2 Abbreviations

10.3 Research Methodology

10.3.1 Coverage

10.3.2 Secondary Research

10.3.3 Primary Research

10.3.4 Expert Panel Validation

10.4 Contact Us

10.5 Disclaimer

10.6 Sources

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards